|
AIM Vaccine Co., Ltd. (6660.HK) DCF Valuation
CN | Healthcare | Biotechnology | HKSE
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
AIM Vaccine Co., Ltd. (6660.HK) Bundle
Explore the financial future of AIM Vaccine Co., Ltd. (6660HK) with our user-friendly DCF Calculator! Enter your projections for growth, margins, and expenses to calculate the intrinsic value of AIM Vaccine Co., Ltd. (6660HK) and refine your investment approach.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,019.3 | 1,754.5 | 1,681.8 | 1,354.0 | 1,271.9 | 1,406.8 | 1,556.0 | 1,721.1 | 1,903.6 | 2,105.5 |
| Revenue Growth, % | 0 | 72.12 | -4.14 | -19.49 | -6.06 | 10.61 | 10.61 | 10.61 | 10.61 | 10.61 |
| EBITDA | 263.6 | 674.8 | -483.8 | -259.2 | -2,198.1 | -235.2 | -260.1 | -287.7 | -318.2 | -352.0 |
| EBITDA, % | 25.86 | 38.46 | -28.77 | -19.15 | -172.81 | -16.72 | -16.72 | -16.72 | -16.72 | -16.72 |
| Depreciation | 104.2 | 137.5 | 154.6 | 178.3 | 187.1 | 155.1 | 171.6 | 189.7 | 209.9 | 232.1 |
| Depreciation, % | 10.22 | 7.84 | 9.19 | 13.17 | 14.71 | 11.03 | 11.03 | 11.03 | 11.03 | 11.03 |
| EBIT | 159.5 | 537.3 | -638.4 | -437.5 | -2,385.2 | -348.9 | -385.9 | -426.8 | -472.1 | -522.2 |
| EBIT, % | 15.64 | 30.62 | -37.96 | -32.31 | -187.53 | -24.8 | -24.8 | -24.8 | -24.8 | -24.8 |
| Total Cash | 53.6 | 1,181.3 | 799.9 | 854.6 | 788.8 | 690.1 | 763.3 | 844.3 | 933.8 | 1,032.9 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 476.5 | 931.7 | 1,139.3 | 1,127.5 | 1,076.6 | 944.0 | 1,044.1 | 1,154.9 | 1,277.3 | 1,412.8 |
| Account Receivables, % | 46.74 | 53.11 | 67.74 | 83.27 | 84.64 | 67.1 | 67.1 | 67.1 | 67.1 | 67.1 |
| Inventories | .0 | 270.7 | 393.5 | 540.6 | 546.1 | 342.4 | 378.7 | 418.9 | 463.3 | 512.5 |
| Inventories, % | 0 | 15.43 | 23.4 | 39.93 | 42.94 | 24.34 | 24.34 | 24.34 | 24.34 | 24.34 |
| Accounts Payable | 46.0 | 40.7 | 55.4 | 78.8 | 64.7 | 59.2 | 65.4 | 72.4 | 80.1 | 88.6 |
| Accounts Payable, % | 4.51 | 2.32 | 3.3 | 5.82 | 5.08 | 4.21 | 4.21 | 4.21 | 4.21 | 4.21 |
| Capital Expenditure | .0 | -714.5 | -1,222.9 | -917.6 | -323.1 | -581.3 | -643.0 | -711.2 | -786.6 | -870.0 |
| Capital Expenditure, % | 0 | -40.72 | -72.72 | -67.77 | -25.4 | -41.32 | -41.32 | -41.32 | -41.32 | -41.32 |
| Tax Rate, % | 42.7 | 42.7 | 42.7 | 42.7 | 42.7 | 42.7 | 42.7 | 42.7 | 42.7 | 42.7 |
| EBITAT | 119.4 | 419.4 | -729.0 | -322.1 | -1,366.6 | -267.9 | -296.3 | -327.7 | -362.5 | -400.9 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -206.9 | -888.8 | -2,113.0 | -1,173.3 | -1,471.4 | -363.3 | -897.9 | -993.1 | -1,098.4 | -1,214.9 |
| WACC, % | 4.91 | 4.94 | 5.13 | 4.9 | 4.76 | 4.93 | 4.93 | 4.93 | 4.93 | 4.93 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -3,883.0 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -1,239 | |||||||||
| Terminal Value | -42,359 | |||||||||
| Present Terminal Value | -33,308 | |||||||||
| Enterprise Value | -37,191 | |||||||||
| Net Debt | 1,299 | |||||||||
| Equity Value | -38,489 | |||||||||
| Diluted Shares Outstanding, MM | 1,211 | |||||||||
| Equity Value Per Share | -31.78 |
Benefits You Will Receive
- Comprehensive Financial Model: Leverage AIM Vaccine Co., Ltd.'s (6660HK) actual data for accurate DCF valuation.
- Complete Forecast Flexibility: Modify revenue growth, profit margins, WACC, and other essential metrics.
- Real-Time Calculations: Immediate updates allow you to view outcomes as you implement changes.
- Professional-Grade Template: A polished Excel file crafted for high-quality valuation presentations.
- Adaptable and Reusable: Designed for versatility, enabling repeated application for in-depth forecasts.
Key Features
- Customizable Forecast Inputs: Adjust essential metrics such as vaccine efficacy, production costs, and research funding.
- Instant DCF Valuation: Quickly computes intrinsic value, NPV, and various financial outputs.
- Industry-Leading Precision: Leverages AIM Vaccine Co., Ltd.'s (6660HK) real-world data for accurate valuation results.
- Streamlined Scenario Testing: Easily evaluate different assumptions and analyze results side by side.
- Efficiency Booster: Remove the hassle of creating intricate valuation models from the ground up.
How It Functions
- 1. Access the Template: Download and open the Excel file containing AIM Vaccine Co., Ltd.'s preloaded data.
- 2. Adjust Assumptions: Modify essential inputs such as growth projections, WACC, and capital expenditures.
- 3. View Results in Real-Time: The DCF model automatically calculates the intrinsic value and NPV.
- 4. Experiment with Scenarios: Analyze various forecasts to evaluate different valuation scenarios.
- 5. Utilize with Assurance: Deliver professional valuation insights to inform your decision-making.
Why Opt for AIM Vaccine Co. (6660HK)?
- User-Friendly Interface: Crafted for both novices and seasoned users.
- Customizable Parameters: Effortlessly adjust inputs for your specific analysis needs.
- Real-Time Updates: Instantly observe changes in AIM's valuation as you tweak inputs.
- Ready-to-Use Data: Comes pre-loaded with AIM's actual financial metrics for swift evaluations.
- Preferred by Experts: Frequently utilized by investors and analysts for making well-informed decisions.
Who Should Use AIM Vaccine Co., Ltd. (6660HK)?
- Investors: Evaluate AIM Vaccine Co.’s valuation prior to trading its shares.
- CFOs and Financial Analysts: Optimize valuation methodologies and validate forecasts.
- Startup Founders: Discover how established biotech firms like AIM Vaccine Co. are valued.
- Consultants: Produce comprehensive valuation reports for your clients.
- Students and Educators: Utilize real-time data to practice and teach valuation strategies.
Contents of the Template
- Pre-Filled DCF Model: AIM Vaccine Co., Ltd.'s financial data preloaded for immediate analysis.
- WACC Calculator: Comprehensive calculations for the Weighted Average Cost of Capital.
- Financial Ratios: Assess AIM Vaccine Co., Ltd.'s profitability, leverage, and operational efficiency.
- Editable Inputs: Modify assumptions such as growth rates, profit margins, and CAPEX to align with your scenarios.
- Financial Statements: Annual and quarterly reports provided for an in-depth review.
- Interactive Dashboard: Effortlessly visualize essential valuation metrics and outcomes.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.